{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:03:46Z","timestamp":1790633026940,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.cll.2021.03.003","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T17:19:47Z","timestamp":1619284787000},"page":"203-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Mass Spectrometry Approaches to Myeloma and Amyloidosis"],"prefix":"10.1016","volume":"41","author":[{"given":"David L.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.cll.2021.03.003_bib1","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1073\/pnas.1014277108","article-title":"Determinism and stochasticity during maturation of the zebrafish antibody repertoire","volume":"108","author":"Jiang","year":"2011","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"13","key":"10.1016\/j.cll.2021.03.003_bib2","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cll.2021.03.003_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A\u00a0long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2021.03.003_bib4","first-page":"1","article-title":"Newly diagnosed myeloma in 2020","volume":"40","author":"Moreau","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.cll.2021.03.003_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clinbiochem.2017.05.001","article-title":"Laboratory testing for monoclonal gammopathies: focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"51","author":"Willrich","year":"2018","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.cll.2021.03.003_bib6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cll.2021.03.003_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"issue":"8","key":"10.1016\/j.cll.2021.03.003_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejim.2013.10.007","article-title":"Systemic amyloidoses: what an internist should know","volume":"24","author":"Palladini","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/PAP.0b013e3182a92dc3","article-title":"Modern approaches to the treatment of amyloidosis: the critical importance of early detection in surgical pathology","volume":"20","author":"Picken","year":"2013","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"10.1016\/j.cll.2021.03.003_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/imj.12288","article-title":"How to diagnose amyloidosis","volume":"44","author":"Mollee","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.cll.2021.03.003_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12014-016-9133-x","article-title":"Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry","volume":"13","author":"Mollee","year":"2016","journal-title":"Clin Proteomics"},{"issue":"5","key":"10.1016\/j.cll.2021.03.003_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-018-0080-9","article-title":"Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018","volume":"8","author":"Gertz","year":"2018","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.cll.2021.03.003_bib14","doi-asserted-by":"crossref","first-page":"e01371","DOI":"10.1002\/brb3.1371","article-title":"Advances in the treatment of hereditary transthyretin amyloidosis: a review","volume":"9","author":"Gertz","year":"2019","journal-title":"Brain Behav"},{"issue":"2","key":"10.1016\/j.cll.2021.03.003_bib15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.2008060614","article-title":"Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis","volume":"20","author":"Gillmore","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.cll.2021.03.003_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5858\/2008-132-14a-UOIFTA","article-title":"Unreliability of immunohistochemistry for typing amyloid deposits","volume":"132","author":"Solomon","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.5858\/2007-131-917-TOAIRB","article-title":"Typing of amyloidosis in renal biopsies: diagnostic pitfalls","volume":"131","author":"Satoskar","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.cll.2021.03.003_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/path.1759","article-title":"Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology","volume":"206","author":"Bergstrom","year":"2005","journal-title":"J\u00a0Pathol"},{"issue":"10","key":"10.1016\/j.cll.2021.03.003_bib19","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/TP.0b013e31824b3749","article-title":"Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis","volume":"93","author":"Gustafsson","year":"2012","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.cll.2021.03.003_bib20","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis","volume":"111","author":"Mangione","year":"2014","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.5858\/2007-131-850-TBOSAT","article-title":"The burden of \"sticky\" amyloid: typing challenges","volume":"131","author":"Picken","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"4\u20135","key":"10.1016\/j.cll.2021.03.003_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10408363.2013.838206","article-title":"Characterization of immunoglobulin by mass spectrometry with applications for the clinical laboratory","volume":"50","author":"Murray","year":"2013","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"3","key":"10.1016\/j.cll.2021.03.003_bib23","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00216-010-4361-9","article-title":"An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions","volume":"399","author":"Dekker","year":"2010","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.cll.2021.03.003_bib24","doi-asserted-by":"crossref","DOI":"10.1021\/pr5000544","article-title":"Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS\/MS","author":"Barnidge","year":"2014","journal-title":"J\u00a0Proteome Res"},{"issue":"9\u201310","key":"10.1016\/j.cll.2021.03.003_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/prca.201300077","article-title":"Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients","volume":"8","author":"Remily-Wood","year":"2014","journal-title":"Proteomics Clin Appl"},{"issue":"1","key":"10.1016\/j.cll.2021.03.003_bib26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1373\/clinchem.2015.242651","article-title":"Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration","volume":"62","author":"Bergen","year":"2016","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.cll.2021.03.003_bib27","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.jproteome.7b00890","article-title":"Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies","volume":"17","author":"Zajec","year":"2018","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.cll.2021.03.003_bib28","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jproteome.9b00705","article-title":"Integrating serum protein electrophoresis with mass spectrometry, A new workflow for M-protein detection and quantification","author":"Zajec","year":"2020","journal-title":"J\u00a0Proteome Res"},{"issue":"7","key":"10.1016\/j.cll.2021.03.003_bib29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2020.04.002","article-title":"Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma","volume":"22","author":"Martins","year":"2020","journal-title":"J\u00a0Mol Diagn"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib30","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1021\/pr901114w","article-title":"Sequencing and quantifying IgG fragments and antigen-binding regions by mass spectrometry","volume":"9","author":"de Costa","year":"2010","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.cll.2021.03.003_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fimmu.2014.00022","article-title":"Immunoglobulin and T Cell receptor genes: IMGT((R)) and the birth and rise of immunoinformatics","volume":"5","author":"Lefranc","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.cll.2021.03.003_bib32","doi-asserted-by":"crossref","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy","author":"Barnidge","year":"2014","journal-title":"J\u00a0Proteome Res"},{"issue":"11","key":"10.1016\/j.cll.2021.03.003_bib33","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1021\/pr5005967","article-title":"Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry","volume":"13","author":"Barnidge","year":"2014","journal-title":"J\u00a0Proteome Res"},{"issue":"3","key":"10.1016\/j.cll.2021.03.003_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjh.13003","article-title":"Detecting monoclonal light chains in urine: microLC-ESI-Q-TOF mass spectrometry compared to immunofixation electrophoresis","volume":"167","author":"Botz","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2021.03.003_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rcm.7314","article-title":"Using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry to detect monoclonal immunoglobulin light chains in serum and urine","volume":"29","author":"Barnidge","year":"2015","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"10","key":"10.1016\/j.cll.2021.03.003_bib36","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.cll.2021.03.003_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1373\/clinchem.2015.253781","article-title":"Screening method for M-proteins in serum using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Kohlhagen","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.cll.2021.03.003_bib38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clinbiochem.2017.08.013","article-title":"Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences","volume":"51","author":"McCudden","year":"2018","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cll.2021.03.003_bib39","article-title":"Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab","author":"Kohlhagen","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"10.1016\/j.cll.2021.03.003_bib40","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ajh.24772","article-title":"The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic","volume":"92","author":"Milani","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.cll.2021.03.003_bib41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41375-018-0194-x","article-title":"Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.cll.2021.03.003_bib42","doi-asserted-by":"crossref","first-page":"E368","DOI":"10.1002\/ajh.25244","article-title":"MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms","volume":"93","author":"Kourelis","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cll.2021.03.003_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020005604","article-title":"Sialic acid bearing paraproteins are implicated in Heparin-like Coagulopathy in myeloma patients","author":"Saadalla","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cll.2021.03.003_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-0940-8","article-title":"N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression","author":"Dispenzieri","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2021.03.003_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25843","article-title":"Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease","author":"Sidana","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.cll.2021.03.003_bib46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s13361-017-1602-6","article-title":"Analysis of monoclonal antibodies in human serum as a model for clinical monoclonal gammopathy by use of 21 tesla FT-ICR top-down and middle-down MS\/MS","volume":"28","author":"He","year":"2017","journal-title":"J\u00a0Am Soc Mass Spectrom"},{"issue":"4","key":"10.1016\/j.cll.2021.03.003_bib47","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1021\/acs.jproteome.5b00015","article-title":"Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies","volume":"14","author":"Dasari","year":"2015","journal-title":"J\u00a0Proteome Res"},{"issue":"5","key":"10.1016\/j.cll.2021.03.003_bib48","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/leu.2017.60","article-title":"Monoclonal antibody therapy in multiple myeloma","volume":"31","author":"Touzeau","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib49","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(20)30105-8","article-title":"Daratumumab: a game changer in myeloma therapy","volume":"7","author":"Ludwig","year":"2020","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.cll.2021.03.003_bib50","first-page":"421","article-title":"Identification of friend or foe: the laboratory Challenge of differentiating M-proteins from monoclonal antibody therapies","volume":"1","author":"Mills","year":"2017","journal-title":"J\u00a0Appl Lab Med"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib51","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1515\/cclm-2015-1023","article-title":"Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation","volume":"54","author":"Willrich","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cll.2021.03.003_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2016.09.015","article-title":"Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood","author":"Murata","year":"2018","journal-title":"Clin Biochem"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib53","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib54","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2018-05-848986","article-title":"A\u00a0universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference","volume":"132","author":"Mills","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cll.2021.03.003_bib55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cca.2019.02.017","article-title":"MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins","volume":"492","author":"Moore","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.cll.2021.03.003_bib56","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin Chem"},{"issue":"18","key":"10.1016\/j.cll.2021.03.003_bib57","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus recommendations for standard investigative workup: report of the international myeloma Workshop Consensus panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cll.2021.03.003_bib58","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.cll.2021.03.003_bib59","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib60","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1515\/cclm-2015-0917","article-title":"Monitoring free light chains in serum using mass spectrometry","volume":"54","author":"Barnidge","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"10.1016\/j.cll.2021.03.003_bib61","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1373\/clinchem.2018.299461","article-title":"Direct detection of monoclonal free light chains in serum by use of immunoenrichment-coupled MALDI-TOF mass spectrometry","volume":"65","author":"Sepiashvili","year":"2019","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.cll.2021.03.003_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-020-0291-8","article-title":"Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis","volume":"10","author":"Dispenzieri","year":"2020","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.cll.2021.03.003_bib63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cll.2021.03.003_bib64","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3389\/fonc.2020.00860","article-title":"Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches","volume":"10","author":"Kostopoulos","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.cll.2021.03.003_bib65","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.cll.2021.03.003_bib66","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1038\/bcj.2017.75","article-title":"High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma","volume":"7","author":"Mills","year":"2017","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.cll.2021.03.003_bib67","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1182\/blood-2011-07-365510","article-title":"Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue","volume":"119","author":"Brambilla","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2021.03.003_bib68","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jclinpath-2014-202722","article-title":"A\u00a0comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue","volume":"68","author":"Gilbertson","year":"2015","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.cll.2021.03.003_bib69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0076-6879(06)12004-2","article-title":"Characterization of systemic amyloid deposits by mass spectrometry","volume":"412","author":"Murphy","year":"2006","journal-title":"Methods Enzymol"},{"issue":"24","key":"10.1016\/j.cll.2021.03.003_bib70","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cll.2021.03.003_bib71","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3324\/haematol.2013.102764","article-title":"Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics","volume":"99","author":"Vrana","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.cll.2021.03.003_bib72","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1021\/pr4011475","article-title":"Clinical proteome informatics workbench detects pathogenic mutations in hereditary amyloidoses","volume":"13","author":"Dasari","year":"2014","journal-title":"J\u00a0Proteome Res"},{"issue":"9","key":"10.1016\/j.cll.2021.03.003_bib73","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.cll.2021.03.003_bib74","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2015111228","article-title":"Novel type of renal amyloidosis derived from apolipoprotein-CII","volume":"28","author":"Nasr","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.cll.2021.03.003_bib75","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1681\/ASN.2016090951","article-title":"Hereditary lysozyme amyloidosis variant p.Leu102Ser Associates with unique Phenotype","volume":"28","author":"Nasr","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.cll.2021.03.003_bib76","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ekir.2018.04.009","article-title":"Apolipoprotein CII amyloidosis associated with p.Lys41Thr mutation","volume":"3","author":"Sethi","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1016\/j.cll.2021.03.003_bib77","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.mayocp.2018.06.016","article-title":"A\u00a0patient with hereditary ATTR and a novel AGel p.Ala578Pro amyloidosis","volume":"93","author":"Sridharan","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cll.2021.03.003_bib78","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.1038\/ncomms10353","article-title":"D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile","volume":"7","author":"Valleix","year":"2016","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.cll.2021.03.003_bib79","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2016-10-743997","article-title":"Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry","volume":"129","author":"Kourelis","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cll.2021.03.003_bib80","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/PAS.0b013e318272fe19","article-title":"Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder","volume":"37","author":"Grogg","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.cll.2021.03.003_bib81","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.clml.2016.08.004","article-title":"Polyclonal localized light chain amyloidosis-A distinct Entity?","volume":"16","author":"Ravindran","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.cll.2021.03.003_bib82","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ki.2008.152","article-title":"Leukocyte chemotactic factor 2: a novel renal amyloid protein","volume":"74","author":"Benson","year":"2008","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.cll.2021.03.003_bib83","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2013-07-517938","article-title":"Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States","volume":"123","author":"Mereuta","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.cll.2021.03.003_bib84","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.jacc.2017.02.047","article-title":"Apolipoprotein A-IV-associated Cardiac amyloidosis","volume":"69","author":"Bois","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.cll.2021.03.003_bib85","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ekir.2017.07.009","article-title":"Hereditary renal amyloidosis associated with a novel apolipoprotein A-II variant","volume":"2","author":"Prokaeva","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.cll.2021.03.003_bib86","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/path.5203","article-title":"A\u00a0novel age-related venous amyloidosis derived from EGF-containing fibulin-like extracellular matrix protein 1","volume":"247","author":"Tasaki","year":"2019","journal-title":"J\u00a0Pathol"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271221000032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271221000032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:57:25Z","timestamp":1759449445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271221000032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0272271221000032"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2021.03.003","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Mass Spectrometry Approaches to Myeloma and Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2021.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}